MovDisordV3, Main, Merge, bibRecord, 005283

Long-term botulinum toxin efficacy, safety, and immunogenicity

Identifieur interne : 005283 ( Main/Merge ); précédent : 005282; suivant : 005284

Long-term botulinum toxin efficacy, safety, and immunogenicity

Auteurs : Nicte I. Mejia [États-Unis] ; Kevin Dat Vuong [États-Unis] ; Joseph Jankovic [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0281345

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Dystonie, Long terme, Bontoxilysin, Sécurité, Immunogénicité, Complication.

English descriptors

KwdEn :
- Bontoxilysin, Complication, Dystonia, Immunogenicity, Long term, Nervous system diseases, Safety.

Abstract

To determine the long-term efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal follow-up data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously for at least 12 years (mean 15.8 ± 1.5 years). Their mean response rating after the last injection, based one a previously described scale 0-to-4 scale (0 = no effect; 4 = marked improvement) was 3.7 ± 0.6 and the mean total duration of response was 15.4 ± 3.4 weeks. Although the latency and total duration of the response to treatment have not changed over time, the peak duration of response (P < 0.005) and dose per visit (P < 0.0001) have increased since the initial visit. Furthermore, global rating (P < 0.02) and peak effect (P < 0.05) have improved. In total, 20 adverse events occurred in 16 of 45 (35.6%) patients after their initial visit and 11 adverse events in 10 of 45 (22.2%) patients at their most recent injection visit. Antibody (Ab) testing was carried out in 22 patients due to nonresponsiveness; blocking Abs were confirmed by the mouse protection assay in 4 of 22 (18%) patients. Of the Ab-negative patients, 16 resumed responsiveness after dose adjustments and2 persisted as nonrespondents. Except for I patient, the 4 Ab-positive and the 2 clinical nonresponders are being treated with BTX-B. This longest reported follow-up of BTX injections confirms the long-term efficacy and safety of this treatment.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001E89
to stream PascalFrancis, to step Curation: 000E32
to stream PascalFrancis, to step Checkpoint: 001E05

Links to Exploration step

Pascal:05-0281345

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term botulinum toxin efficacy, safety, and immunogenicity</title>
<author><name sortKey="Mejia, Nicte I" sort="Mejia, Nicte I" uniqKey="Mejia N" first="Nicte I." last="Mejia">Nicte I. Mejia</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dat Vuong, Kevin" sort="Dat Vuong, Kevin" uniqKey="Dat Vuong K" first="Kevin" last="Dat Vuong">Kevin Dat Vuong</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0281345</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0281345 INIST</idno>
<idno type="RBID">Pascal:05-0281345</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E89</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E32</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E05</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Mejia N:long:term:botulinum</idno>
<idno type="wicri:Area/Main/Merge">005283</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term botulinum toxin efficacy, safety, and immunogenicity</title>
<author><name sortKey="Mejia, Nicte I" sort="Mejia, Nicte I" uniqKey="Mejia N" first="Nicte I." last="Mejia">Nicte I. Mejia</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dat Vuong, Kevin" sort="Dat Vuong, Kevin" uniqKey="Dat Vuong K" first="Kevin" last="Dat Vuong">Kevin Dat Vuong</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Complication</term>
<term>Dystonia</term>
<term>Immunogenicity</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Safety</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Dystonie</term>
<term>Long terme</term>
<term>Bontoxilysin</term>
<term>Sécurité</term>
<term>Immunogénicité</term>
<term>Complication</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To determine the long-term efficacy of botulinum toxin (BTX) treatments, we analyzed longitudinal follow-up data on 45 patients (32 women; mean age, 68.8 years) currently followed in the Baylor College of Medicine Movement Disorders Clinic, who have received BTX treatments continuously for at least 12 years (mean 15.8 ± 1.5 years). Their mean response rating after the last injection, based one a previously described scale 0-to-4 scale (0 = no effect; 4 = marked improvement) was 3.7 ± 0.6 and the mean total duration of response was 15.4 ± 3.4 weeks. Although the latency and total duration of the response to treatment have not changed over time, the peak duration of response (P < 0.005) and dose per visit (P < 0.0001) have increased since the initial visit. Furthermore, global rating (P < 0.02) and peak effect (P < 0.05) have improved. In total, 20 adverse events occurred in 16 of 45 (35.6%) patients after their initial visit and 11 adverse events in 10 of 45 (22.2%) patients at their most recent injection visit. Antibody (Ab) testing was carried out in 22 patients due to nonresponsiveness; blocking Abs were confirmed by the mouse protection assay in 4 of 22 (18%) patients. Of the Ab-negative patients, 16 resumed responsiveness after dose adjustments and2 persisted as nonrespondents. Except for I patient, the 4 Ab-positive and the 2 clinical nonresponders are being treated with BTX-B. This longest reported follow-up of BTX injections confirms the long-term efficacy and safety of this treatment.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
<settlement><li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Mejia, Nicte I" sort="Mejia, Nicte I" uniqKey="Mejia N" first="Nicte I." last="Mejia">Nicte I. Mejia</name>
</region>
<name sortKey="Dat Vuong, Kevin" sort="Dat Vuong, Kevin" uniqKey="Dat Vuong K" first="Kevin" last="Dat Vuong">Kevin Dat Vuong</name>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005283 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005283 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:05-0281345
   |texte=   Long-term botulinum toxin efficacy, safety, and immunogenicity
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-term botulinum toxin efficacy, safety, and immunogenicity

Long-term botulinum toxin efficacy, safety, and immunogenicity

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri